Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 11.22 USD -1.92%
Market Cap: 358.7m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Gross Margin
Delcath Systems Inc

81.3%
Current
75%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.3%
=
Gross Profit
18.4m
/
Revenue
22.6m

Gross Margin Across Competitors

Country US
Market Cap 365.7m USD
Gross Margin
81%
Country US
Market Cap 198.3B USD
Gross Margin
56%
Country US
Market Cap 189.1B USD
Gross Margin
67%
Country US
Market Cap 140.4B USD
Gross Margin
64%
Country US
Market Cap 132.3B USD
Gross Margin
69%
Country IE
Market Cap 104.2B USD
Gross Margin
65%
Country US
Market Cap 65.2B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.1B USD
Gross Margin
79%
Country CN
Market Cap 309.1B CNY
Gross Margin
64%
Country US
Market Cap 36.2B USD
Gross Margin
41%
No Stocks Found

Delcath Systems Inc
Glance View

Market Cap
358.7m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.95 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.3%
=
Gross Profit
18.4m
/
Revenue
22.6m
What is the Gross Margin of Delcath Systems Inc?

Based on Delcath Systems Inc's most recent financial statements, the company has Gross Margin of 81.3%.